Global Coalition for Adaptive Research

Glioblastoma Adaptive Global innovative learning environment (gbm agile), gcar's initial and most advanced initiative, is a Global phase 2/3 Adaptive platform trial, designed to evaluate multiple investigational treatments for glioblastoma over time in an effort to improve patient outcomes. Gbm agile has been open and enrolling patients since july 2019 with over 1,900 patients screened to date. In 2023, several publications /presentations were conducted to present data and latest progress to the Research community, including the american association for cancer Research, european association of neuro-oncology, and the society for neuro-oncology. Additionally, gcar provides on-going support to the gbm Research and clinical community through philanthropic donations to advocacy groups, as well as education, outreach and clinical community engagement. To promote brain cancer awareness in 2023, gcar participated in advocacy partner fund raising events, panel discussions, and academic conferences. Notable highlights included ringing the nasdaq closing bell alongside patients, advocacy partners, and pharmaceutical partners to promote brain tumor awareness month and participating in the white house cancer moonshot forum on brain cancer.

Remap-covid, a sub-study of remap-cap (a randomized, embedded, multifactorial, Adaptive platform trial for community-acquired pneumonia), was developed to test multiple interventions for the treatment of patients hospitalized with covid-19. Gcar sponsored remap-covid in the us, with the university of pittsburgh as the us regional coordinating center. Partnering with academia, industry and multiple healthcare systems, over 500 patients were randomized within four domains in the us. With the pandemic winding down, the trial was closed in june 2023. In 2023, 2 clinical study reports were submitted to the agency and 4 key publications were presented via the journal of the american medical association, new england journal of medicine, and intensive care medicine.

Programs in development. Additional efforts are focused on activities to support the launch, design, education, outreach, and clinical community engagement for multiple programs in development including biliary tract cancer, ovarian cancer, neurofibromatosis, and pancreatic cancer, all rare and deadly diseases with critical need for further development of new treatment options for patients.1 smaller federal program to support covid Research was in wind-down stage in 2023 (ended february 2024).